Semaglutide implant - Vivani Medical
Alternative Names: NPM-133; NPM-139; Semaglutide NanoPortal implant - Vivani MedicalLatest Information Update: 22 May 2026
At a glance
- Originator Nano Precision Medical
- Developer Vivani Medical
- Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus
Most Recent Events
- 14 May 2026 Vivani Medical plans a pre-IND meeting with US FDA for the phase II dose-ranging study in Obesity
- 14 May 2026 Vivani Medical plans a phase II dose ranging trial for Obesity (implant) in 2027
- 27 Mar 2026 Vivani Medical plans a phase I SLIM-1 trial for Obesity in Australia in mid 2026 (SC, Implant) (NCT07430059)